211 related articles for article (PubMed ID: 28445850)
1. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
3. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
[TBL] [Abstract][Full Text] [Related]
4. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
5. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
Huang L; Lizak P; Dvorak CC; Aweeka F; Long-Boyle J
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():194-9. PubMed ID: 24820973
[TBL] [Abstract][Full Text] [Related]
7. A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry.
Ansari M; Uppugunduri CR; Déglon J; Théorêt Y; Versace F; Gumy-Pause F; Ozsahin H; Dayer P; Desmules J; Daali Y
Rapid Commun Mass Spectrom; 2012 Jun; 26(12):1437-46. PubMed ID: 22592987
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Andersson BS; Thall PF; Ma J; Valdez BC; Bassett R; Chen J; Ahmed S; Alousi A; Bashir Q; Ciurea S; Gulbis A; Cool R; Kawedia J; Hosing C; Kebriaei P; Kornblau S; Myers A; Oran B; Rezvani K; Shah N; Shpall E; Parmar S; Popat UR; Nieto Y; Champlin RE
Bone Marrow Transplant; 2022 Aug; 57(8):1295-1303. PubMed ID: 35610308
[TBL] [Abstract][Full Text] [Related]
11. A rapid HPLC-MS/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation.
Jinjie Y; Sun N; Zhang S; Feng X; Chen X; Zhao D; Zhao L
Biomed Chromatogr; 2020 Sep; 34(9):e4898. PubMed ID: 32428257
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan.
French D; Sujishi KK; Long-Boyle JR; Ritchie JC
Ther Drug Monit; 2014 Apr; 36(2):169-74. PubMed ID: 24625541
[TBL] [Abstract][Full Text] [Related]
13. A Simple and Accurate Liquid Chromatography-Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Busulfan in Plasma.
Lee EJ; Park N; Lee SH; Lee W; Kim HS; Chun S; Min WK
Ann Clin Lab Sci; 2019 Mar; 49(2):212-217. PubMed ID: 31028066
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous determination of clofarabine and cytarabine in human plasma by LC-MS/MS.
Büttner B; Oertel R; Schetelig J; Middeke JM; Bornhäuser M; Seeling A; Knoth H
J Pharm Biomed Anal; 2016 Jun; 125():286-91. PubMed ID: 27060437
[TBL] [Abstract][Full Text] [Related]
16. High-Throughput Validated Method for the Quantitation of Busulfan in Plasma Using Ultrafast SPE-MS/MS.
Danso D; Jannetto PJ; Enger R; Langman LJ
Ther Drug Monit; 2015 Jun; 37(3):319-24. PubMed ID: 25970507
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
[TBL] [Abstract][Full Text] [Related]
19. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
[TBL] [Abstract][Full Text] [Related]
20. A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry.
Versace F; Uppugunduri CR; Krajinovic M; Théorêt Y; Gumy-Pause F; Mangin P; Staub C; Ansari M
Anal Bioanal Chem; 2012 Oct; 404(6-7):1831-8. PubMed ID: 22918536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
